Use this button to switch between dark and light mode.

FTC Checks up on the Health of Competition in Healthcare

February 27, 2024 (1 min read)

FTC Chair Lina Khan told a conference of the American Medical Association on February 14, 2024, that the healthcare market is under the microscope in the Commission’s push for greater competition across the economy. Recent efforts by the FTC in this space include requesting public comment on how powerful “middlemen” in the generic drug market may contribute to shortages of these drugs. The agency also announced a March 5 virtual workshop to examine the role of private equity’s investment in healthcare markets. Additionally, the FTC issued a recent comment supporting the government’s right to “march in” to invalidate a patent if the patent holder is charging an excessive price on a patented drug developed with taxpayer-funded research.

The Antitrust Agency Developments Tracker covers these developments and other FTC and DOJ non-case-related efforts, policy statements, and goings-on at the agencies.  


Related Content

  • DOJ/FTC Antitrust Case Tracker (Merger)
    Learn about FTC actions challenging healthcare mergers, such as the January 2024 challenge of Novant’s acquisition of two North Carolina hospitals and IQVIA and Propel Media abandoning their proposed merger in January 2024 after a district court temporarily blocked it.
  • Healthcare Antitrust Resource Kit
    Access guidance on antitrust issues in M&A transactions involving hospitals and other providers, commercial conduct in the healthcare industry, and antitrust risks specific to the pharmaceutical industry.

Practical Guidance Updates
Featuring the latest updates from your Practical Guidance account.


Experience results today with practical guidance, legal research, and data-driven insights—all in one place.

Experience Lexis+